News Releases

Ron Dadino appointed Vice President, Pharmaceutical Development & Operations, Cardiovascular Interventions Greg Kopia, Ph.D., CMPP appointed Director, Pre-Clinical Development, Cardiovascular Interventions Ziv Belsky appointed Vice President, Research & Development, Cardiac Neuromodulation New

Eric A. Rose, M.D., biotech and medical device business leader as well as world-renowned cardiac surgeon and scientist who performed the landmark achievement of the first successful pediatric heart transplant Jason Aryeh, life sciences industry expert, investment fund manager, and Director of

Ms. Wheeler brings an extensive track record in marketing, strategy and commercial program development New Hope, PA – Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing high impact, high value, evidence-based therapeutic solutions for medical

Immediate, Substantial, and Sustained Reduction in Blood Pressure Demonstrates Potential to Offer Highly Differentiated, Breakthrough Treatment for Hypertension San Diego, CA – Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing transformational

Excellent Long-Term Safety and Efficacy Profile Demonstrate Potential to Offer Valuable New Treatment for Coronary In-Stent Restenosis San Diego, CA – Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing transformational therapeutic devices

American Heart Association Journal 3-months data from Moderato-HTN first-in-human clinical study was published in the American Heart Association Journal. The study was an open-label, single-arm, multicenter, prospective trial investigating the safety and efficacy of BackBeat PHC pacing therapy in

International Conference for Innovation (ICI), Tel Aviv, Israel BackBeat’s abstract entitled “Two-Year Experience with Programmable Hypertension Control Therapy: A Novel Treatment for Hypertension” was awarded best abstract at the International Conference for Innovation (ICI) that took place in Tel

JACC: Cardiovascular Interventions Angiographic results and 1-year clinical outcomes of the SABRE (Sirolimus Angioplasty Balloon for Coronary In-Stent Restenosis) trial were published in JACC: Cardiovascular Interventions, October 2017. ABSTRACT. Objectives The aim of this first-in-human study was

Transcatheter Cardiovascular Therapeutics (TCT), Washington, DC. New Hope, PA – BackBeat Medical Inc. today announced that the company's patented Programmable Hypertension Control (PHC) therapy received first place in the Shark Tank Innovation Competition at the Transcatheter Cardiovascular

The Journal of Innovation in Cardiac Rhythm Management BackBeat Medical Inc. today announced the presentation of data demonstrating a significant and sustained reduction in blood pressure in patients with hypertension using the company's patented cardiac pacing-based treatment.